Pharma News

Researchers at the University of East Anglia have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods.

New research shows that the Prostate Screening EpiSwitch (PSE) blood test is 94 per cent accurate – beating the currently used prostate-specific antigen (PSA) blood test.

The research team say that the new test shows significant potential as an accurate and rapid cancer screening diagnostic.

National Action Plan on containment of Antimicrobial Resistance (NAP-AMR) was launched on 19th April, 2017. National AMR surveillance network of state medical college labs (NARS-Net) has been established to generate quality data on AMR for priority bacterial pathogens of public health importance.

AMR surveillance network of state medical college labs (NARS-Net) established to generate quality data on AMR.

Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets. This product would be manufactured at Lupin’s Nagpur facility in India.

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries.

Pfizer said that it has conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities.

Alkem has announced the launch of its novel anti-infective Ceftazidime-Avibactam injection, under the brand name, Zidavi in India. It is known to be effective against multi-drug resistance, MDR infections.

In India, with the rise in carbapenem-resistant Gram-negative organisms, there is a need for treatments more effective than the existing antibiotics. Zidavi is a 3rd generation antibiotic.

A new Cedars-Sinai study suggests that some patients diagnosed with behavioral-variant frontotemporal dementia (bvFTD)—an incurable condition that robs patients of the ability to control their behavior and cope with daily living—may instead have a cerebrospinal fluid leak, which is often treatable.

Researchers say these findings, published in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research and Clinical Interventions, may point the way to a cure.

An innovative temperature-compensation mechanism for oscillating chemical reactions based on temperature-responsive gels has been recently reported by researchers at Tokyo Tech. Their experimental findings, alongside a detailed mathematical analysis, hint at the possibility that circadian rhythms found in nature may all rely on a similar mechanism, allowing their period to remain independent of temperature.

The World Health Organization (WHO) and Gilead Sciences have signed a new agreement for the donation of 304,700 vials of AmBisome (liposomal amphotericin B for injection), for the treatment of visceral leishmaniasis in countries most impacted by the disease, extending their previous agreement to 2025.

Glenmark Pharmaceuticals Ltd, an innovation-driven, global pharmaceutical company, is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.